After a Confirmed Human Death from the Avian Influenza Virus A (H5N2), Investors Once Again Target Vaccine Manufacturers. The World Health Organization (WHO) Confirmed on Wednesday Evening that for the First Time, a Human, a Man from Mexico, has Died from the New Variant of the Virus. Previous Deaths from Avian Influenza Viruses were Caused by the Virus Type A (H5N1).

The virus is typically transmitted through contact with infected birds. In Mexico, the virus was detected at a poultry farm in the state of Michoacán, near the border with the State of Mexico, where the infected person lived.

Already a few days ago, it became known that the USA is close to a deal with Moderna to finance the late-stage clinical development of an experimental mRNA avian flu vaccine. Government funding could amount to up to ten million US dollars and, in case of a successful study, include an obligation to purchase vaccine doses, the "Financial Times" reported.

Here is the translated heading:
"With the first confirmed death from the new virus variant, this news gained renewed importance.

During the COVID-19 pandemic, CureVac fell short of expectations. In 2021, the company had to acknowledge a comparatively lower efficacy of its vaccine candidate and lost a patent dispute with BioNTech in 2023, which involved the violation of intellectual property rights. This led to significant declines in stock prices, and CureVac's twelve-month performance is markedly negative at minus 55 percent.

However, with the recent news about the bird flu virus, investors are once again turning to the stock, which has been on a recovery path since mid-May.